Defendant

Cipla

2 cases as defendant.

Cases
2
Active
1
1 closed
Filed
2017
Top venue
D. New Jersey
1 case

Company profile

Cipla Limited ("Cipla") is an Indian multinational pharmaceutical company headquartered at Cipla House, Peninsula Business Park, Lower Parel, Mumbai. Founded in 1935 by Khwaja Abdul Hamied as Chemical, Industrial & Pharmaceutical Laboratories, it took the Cipla name in 1984. It is publicly listed (BSE: 500087; NSE: CIPLA), an NSE Nifty 50 constituent, with GDRs listed in Luxembourg; the Hamied family promoter group holds roughly a third of the equity. Reported revenue was about ₹25,455 crore (~US$3.0B) in FY24. Employee counts vary widely by source and date (roughly 22,000 to over 45,000), so treat any headcount as approximate.

Products and operations. Cipla develops, manufactures and sells generic and branded-generic prescription medicines, active pharmaceutical ingredients, biosimilars and consumer-healthcare products. Its major therapeutic areas include respiratory (a self-described leadership position in inhalers/asthma), HIV/AIDS — it has described itself as the world's largest manufacturer of antiretrovirals — plus cardio-metabolic, oncology, diabetes and CNS products. It operates dozens of manufacturing sites, largely in India, and holds US and South African subsidiaries (e.g., InvaGen and Exelan in the US; Cipla South Africa).

Litigation posture. Cipla appears in the tracked data exclusively as a defendant: 2 of 2 cases, 0 as plaintiff. That profile is consistent with an operating generic manufacturer defending Hatch-Waxman ANDA suits, not a patent-assertion entity or a two-way litigant. Both tracked matters are Celgene Corporation v. Cipla in the District of New Jersey — a common venue for branded-pharma patent suits, not a plaintiff-friendly NPE forum like the Eastern District of Texas.

Notable cases. The 2017-08-15 case is Celgene's lenalidomide (Revlimid) ANDA action; Cipla filed invalidity and non-infringement counterclaims, and the parties settled in December 2020 on a volume-limited license after March 2022, with unrestricted generic entry no earlier than January 31, 2026. The second matter, Celgene Corp. v. Cipla (D.N.J., filed February 10, 2025, No. 2:25-cv-01147), concerns Cipla's ANDA for generic Pomalyst (pomalidomide). Celgene is now a wholly owned subsidiary of Bristol Myers Squibb.

Celgene Corporation v. Cipla

pending/settled
Docket:
2:20-cv-07759
Court:
D.N.J.
Patents:8530498

Cipla filed an Answer regarding ANDA No. 214618 for 2.5 mg Revlimid. The '498 patent was among the patents-in-suit per Cipla's answer.